What new drug for moderate-to-severe plaque psoriasis was approved by the FDA on March 17, 2026?

Icotyde, also known by its active ingredient icotrokinra, received approval from the U.S. Food and Drug Administration (FDA) on March 18, 2026, for the treatment of moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older who are candidates for systemic therapy or phototherapy. This approval marks a significant advancement in dermatology as Icotyde is the first and only targeted oral peptide designed to precisely block the interleukin-23 (IL-23) receptor, a key driver of inflammation in psoriasis.

Plaque psoriasis is a chronic, immune-mediated inflammatory skin disease affecting millions, characterized by thick, scaly patches of skin. The condition is driven by a dysregulation of the IL-23/type 17 T cell axis, which fuels the inflammatory cascade responsible for these characteristic plaques. While injectable biologics targeting IL-23 have been available, Icotyde offers a novel approach by providing a once-daily oral pill that mimics the receptor-blocking activity of these injectable drugs. This oral administration can be a "game-changer" for many patients who may have an aversion to needles or are looking for a more convenient treatment option.

The FDA's decision to approve Icotyde was based on robust data from the ICONIC clinical development program, which included four Phase 3 studies involving approximately 2,500 patients. These trials demonstrated that Icotyde achieved high rates of skin clearance and maintained a favorable safety profile. Approximately 70% of patients achieved clear or almost clear skin, and 55% saw a 90% reduction in their Psoriasis Area and Severity Index (PASI 90) response at Week 16. This innovative oral peptide combines effective skin clearance with the convenience of a once-daily pill, offering a new standard for managing this challenging skin condition.